Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

miltefosine

An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity. Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt
hexadecylphosphocholine
Miltefosin
Miltefosina
Miltefosinum
Foreign brand name:Miltex
Abbreviation:HDPC
Code name:D-18506
Chemical structure:2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt
Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate
n-Hexadecylphosphorylcholine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search